TCTMD2 个月
What’s Next in Acute and Chronic Phase Antithrombotic Therapy in ACS
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Grant ...
Taiwan News7 天
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct domains of Factor XI. REGN7508 (catalytic domain) is ...